Multiple Sclerosis & Medical Cannabis

Multiple Sclerosis as a Qualifying Condition

Multiple sclerosis (MS) is among the best-supported indications for medical cannabis worldwide. Sativex, a THC:CBD oromucosal spray, is approved in over 25 countries specifically for MS-related spasticity. While not yet approved in the US, it reflects the substantial evidence base for cannabis in MS management.

NJ patients with all forms of MS — relapsing-remitting, secondary progressive, primary progressive — qualify for the medical cannabis program, particularly when they experience spasticity, pain, or other symptoms not adequately controlled by disease-modifying therapies or standard symptomatic medications.

Symptoms Cannabis May Help

• Spasticity and muscle stiffness
• Neuropathic pain
• Sleep disruption
• Bladder dysfunction
• Fatigue (with careful product selection)
• Tremor (some evidence)

Treatment Approach

Our providers are experienced in working with MS patients alongside neurologists. Cannabis therapy for MS typically emphasizes balanced THC:CBD preparations to address spasticity and pain while minimizing cognitive side effects. We provide detailed guidance on product selection, starting dose, and titration.